U.S. Electronic Equipment and Components Stock News

NYSE:BABA
NYSE:BABAMultiline Retail

Alibaba Group Holding (NYSE:BABA) Margin Compression Tests Bullish Earnings Growth Narrative

Alibaba Group Holding (BABA) Q3 2026 earnings snapshot Alibaba Group Holding (BABA) just posted Q3 2026 results with revenue of ¥284.8b and basic EPS of ¥7.03, as investors weigh these numbers against a forecast calling for revenue growth of 9.1% per year and earnings growth of about 19.6% per year. The company has seen quarterly revenue move between ¥236.5b and ¥284.8b over the past six reported periods, while basic EPS has ranged from ¥5.36 to ¥21.07, set against trailing twelve month EPS...
NasdaqGS:SKYW
NasdaqGS:SKYWAirlines

Is It Time To Reassess SkyWest (SKYW) After The Recent Share Price Pullback

Wondering whether SkyWest's current share price reflects its true value, or if the market is mispricing the stock. SkyWest recently closed at US$89.36, with a 0.2% decline over 7 days, a 16.8% decline over 30 days, an 11.7% decline year to date, a 1.1% decline over 1 year, a very large gain over 3 years and a 66.0% gain over 5 years, which may have caught your attention. Recent price moves sit against a backdrop where investors are reassessing airlines and regional carriers in light of...
NYSE:YSS
NYSE:YSSAerospace & Defense

Has York Space Systems (YSS) Fallen Too Far After Recent Share Price Weakness?

If you are wondering whether York Space Systems at around US$17.68 offers value or just extra risk, the key is to separate short term noise from what the current price actually implies. The share price has recently been under pressure, with a 7 day return of 11.5% decline, a 30 day move of 36.9% decline, and a year to date return of 47.4% decline. This naturally raises questions about whether sentiment has swung too far. Recent news coverage has focused on York Space Systems as part of the...
NYSE:UAN
NYSE:UANChemicals

A Look At CVR Partners (UAN) Valuation As Supply Tightens And Ammonia Orders Accelerate

The conflict in Iran that is limiting fertilizer shipments through the Strait of Hormuz has pushed nitrogen producers into focus, with CVR Partners (UAN) drawing attention as supply tightens and ammonia prices respond. See our latest analysis for CVR Partners. At a share price of $131.26, CVR Partners has seen a 30 day share price return of 22.67% and a 90 day share price return of 37.47%, while the 1 year total shareholder return of 93.50% reflects strong long term gains. This suggests that...
NasdaqGS:CTMX
NasdaqGS:CTMXBiotechs

How Investors Are Reacting To CytomX Therapeutics (CTMX) Equity Raise And Encouraging Varseta-M Trial Data

CytomX Therapeutics recently reported full-year 2025 results showing sales of US$76.2 million and a net loss of US$17.37 million, and has just raised roughly US$250.00 million through a follow-on offering of common stock and pre-funded warrants at about US$5.30 per security. At the same time, the company released encouraging Phase 1 data for its EpCAM-targeted ADC Varseta-M in heavily pretreated metastatic colorectal cancer, with a high disease control rate and a safety profile that appears...
NYSE:TTAM
NYSE:TTAMBasic Materials

Titan America Keystone Deal And 2025 Records Reframe Valuation Story

Titan America (NYSE:TTAM) has agreed to acquire Keystone Cement, expanding its presence and capacity in the Mid-Atlantic region. The company reports record revenue, EBITDA and operating cash flows for 2025, despite sector headwinds. These developments have not yet been widely discussed and may reshape Titan America's growth profile and operational footprint. For investors tracking NYSE:TTAM, the stock last closed at $14.71, with a 1 year return of 15.1% and a 12.0% decline year to date...
NYSEAM:PLX
NYSEAM:PLXBiotechs

A Look At Protalix BioTherapeutics (PLX) Valuation After Elfabrio Dosing Approval And Updated 2026 Revenue Guidance

Why Protalix BioTherapeutics is Back on Investors’ Radar Protalix BioTherapeutics (PLX) has drawn fresh attention after the European Commission approved a new Elfabrio dosing regimen for certain Fabry disease patients, alongside updated 2026 revenue guidance that includes a US$25 million regulatory milestone. See our latest analysis for Protalix BioTherapeutics. The Elfabrio dosing news and 2026 guidance update arrive after a mixed share price pattern, with a 28.9% 90 day share price return...
NYSE:VNO
NYSE:VNOOffice REITs

Is It Time To Reconsider Vornado Realty Trust (VNO) After Its Recent Share Price Slide?

For investors considering whether Vornado Realty Trust at around US$26.48 reflects enough potential or already embeds too much optimism, this article breaks down what the current share price really represents. The stock has had a mixed run, with a 1.7% gain over the last 7 days, an 8.8% decline over the last 30 days, a 20.8% decline year to date, a 29.9% decline over 1 year, and a 114.6% return over 3 years, compared with a 32.1% decline over 5 years. Recent coverage around Vornado Realty...
NYSE:THO
NYSE:THOAuto

Is THOR Industries (THO) A Potential Opportunity After Recent Share Price Slide?

Wondering whether THOR Industries at around US$76 a share is a bargain or a value trap? This article walks through the numbers so you can judge whether the current price lines up with the fundamentals. The stock has seen a 7.3% decline over the past week, a 33.5% decline over the past month, and is down 27.6% year to date, while the 1-year return sits at a 2.7% decline. These moves have kept THOR Industries on many watchlists, with investors reacting to ongoing headlines around the broader...
NasdaqCM:OVID
NasdaqCM:OVIDBiotechs

A Look At Ovid Therapeutics (OVID) Valuation After OV329 Trial Update And US$60 Million Financing

Ovid Therapeutics (OVID) has drawn fresh attention after reporting Phase 1 data for its OV329 epilepsy program at a 7 mg dose, alongside plans to expand into new seizure indications backed by about US$60 million in private financing. See our latest analysis for Ovid Therapeutics. The new OV329 data and US$60 million financing arrive after a sharp run in the stock, with a 30 day share price return of 60.84% and a 1 year total shareholder return above 400%, even though the 3 year and 5 year...
NasdaqGS:COLL
NasdaqGS:COLLPharmaceuticals

Collegium Pharmaceutical Expands ADHD Portfolio With AZSTARYS And Valuation Gap

Collegium Pharmaceutical (NasdaqGS:COLL) has entered into a definitive agreement to acquire AZSTARYS. The deal expands Collegium’s ADHD portfolio and secures longer-term product exclusivity for its ADHD offerings. The transaction is described as immediately accretive to adjusted EBITDA. For investors following the ADHD treatment space, this move provides another data point on how branded therapies are being repositioned. Collegium, which focuses on pain and ADHD treatments, is adding...
NasdaqGS:NBTB
NasdaqGS:NBTBBanks

Is It Time To Reassess NBT Bancorp (NBTB) After Recent Share Price Weakness?

If you are wondering whether NBT Bancorp at around US$40.97 is starting to look interesting, the current share price and fundamentals raise some clear valuation questions worth unpacking. The stock has seen a 0.7% decline over the last week, a 10.4% decline over the past month, and a 1.5% decline year to date, while the 1 year, 3 year, and 5 year returns stand at a 1.9% decline, 34.7%, and 21.3% respectively. Recent attention on regional banks, regulatory capital expectations, and investor...
NasdaqGM:FLY
NasdaqGM:FLYAerospace & Defense

Firefly Aerospace’s Record 2025 Reshapes Moon, Defense And Valuation Story

Firefly Aerospace (NasdaqGM:FLY) completed its first commercial moon landing in 2025, expanding its activity beyond Earth orbit missions. The company listed its shares in a high profile IPO in 2025, providing wider access to capital markets. Firefly reported major revenue growth in 2025 and acquired SciTec to deepen its national security and defense related offerings. For investors tracking Firefly Aerospace at a current share price of $22.96, 2025 marked a shift in scale and scope. The...
NYSE:GLOB
NYSE:GLOBIT

Globant Taps AI Cancer Research And Payments Deals As Shares Lag Targets

Globant (NYSE:GLOB) announced an AI focused collaboration with PharmaMar to support cancer drug discovery efforts. The company also agreed a global integration partnership with payments platform Adyen for enterprise clients. Both arrangements position Globant in healthcare and fintech projects tied to drug research and digital payments infrastructure. Globant operates as a digital services and technology company, working with enterprises that are investing in cloud, data and AI based...
NasdaqGM:LUNR
NasdaqGM:LUNRAerospace & Defense

Intuitive Machines (LUNR) Q4 Loss Of US$19.9 Million Tests Profitability Narrative

Intuitive Machines (LUNR) closed FY 2025 with Q4 revenue of US$44.8 million and a basic EPS loss of US$0.17, alongside a net loss of US$19.9 million, while on a trailing 12 month basis revenue was US$210.1 million and EPS stood at a loss of US$0.71 with a net loss of US$83.9 million. Over recent quarters, the company has seen quarterly revenue move from US$62.5 million in Q1 2025 to US$50.3 million in Q2, US$52.4 million in Q3 and US$44.8 million in Q4, with EPS losses ranging between US$0.06...
NYSE:UAMY
NYSE:UAMYMetals and Mining

United States Antimony Contracts Recast Critical Minerals And Tungsten Growth Story

United States Antimony (NYSE:UAMY) secured a U.S. government contract worth more than $248m for antimony ingots in the past week. The company reported an additional $354m in new antimony agreements, expanding its role in critical mineral supply chains. UAMY announced an acquisition of a tungsten asset in Ontario, targeting domestic tungsten production for North America. The company restarted antimony mining in Montana and is increasing processing capacity with active government...
NYSE:TE
NYSE:TEElectrical

T1 Energy Links Mo I Rana Power To AI Data Center Growth

T1 Energy (NYSE:TE) has secured a 50MW grid power allocation from Statnett for its Mo i Rana facility in Norway. The company plans to use this power to advance Mo i Rana as a Nordic AI data center hub. The project is positioned to use low cost, nearly 100% hydroelectric power from the Norwegian grid. This marks an expansion beyond T1 Energy's existing U.S. solar manufacturing focus. For you as an investor, this move indicates that T1 Energy is not just a U.S. solar manufacturing story...
NYSE:LEU
NYSE:LEUOil and Gas

Is It Too Late To Consider Centrus Energy (LEU) After Its Huge Three Year Rally?

Wondering if Centrus Energy at around US$205 a share still offers value, or if the best gains are already behind it? This article breaks down what the current price actually means for you. The stock has been volatile, with a 4.5% decline over the last 7 days and a 24.7% drop year to date. It still shows a 176.1% return over the past year and a very large 3-year gain of around 7x. Recent coverage has focused on Centrus Energy's role in the nuclear fuel supply chain and its position within the...
NasdaqGS:LILA
NasdaqGS:LILATelecom

Is Liberty Latin America (LILA) Offering Value After Recent Share Price Gains?

Wondering whether Liberty Latin America at around US$7.96 is priced for opportunity or already reflects the key information you care about? The stock has returned 5.3% over the last week, 1.5% over the past month, 9.6% year to date and 17.2% over the last year. The 3 year return is 2.4% and the 5 year return is a 41.4% decline. Recent coverage of Liberty Latin America has focused on its position within the broader telecom sector and how investors are reacting to its capital allocation and...
NasdaqGS:PZZA
NasdaqGS:PZZAHospitality

Papa John's Bets On Unified Delivery Platform To Sharpen Competitive Edge

Papa John's International (NasdaqGS:PZZA) has entered into a partnership with Deliverect to deploy a unified Smart Dispatch & Delivery Management platform. The roll out is planned across all US locations, covering order routing, dispatch, and delivery operations. The initiative is focused on centralizing delivery workflows and improving the experience for customers ordering through digital channels. Papa John's International operates as a global pizza delivery and carryout chain, with a...
NasdaqGS:TIGR
NasdaqGS:TIGRCapital Markets

UP Fintech Holding NasdaqGS TIGR Net Margin Jump Challenges Cautious Growth Narratives

UP Fintech Holding (TIGR) has just wrapped up FY 2025 with fourth quarter revenue of US$156.5 million and basic EPS of US$0.25, against a trailing twelve month total of US$538.7 million in revenue and EPS of US$0.97. Over the past year the company has seen revenue move from US$330.7 million to US$538.7 million on a trailing basis, while EPS stepped up from US$0.38 to US$0.97, setting a clear backdrop of expanding profit per share for this latest update. With trailing net margin at 31.7%...
NYSE:NRGV
NYSE:NRGVElectrical

Is Energy Vault (NRGV) Quietly Reframing Its Story Around Data Center And AI Infrastructure?

In March 2026, Energy Vault Holdings reported fourth-quarter 2025 sales of US$153.31 million and a net loss of US$20.73 million, with full-year 2025 sales of US$203.67 million and a net loss of US$103.61 million, both reflecting narrower per-share losses than the prior year. The company also issued 2026 revenue guidance of US$225 million to US$300 million, highlighting expected contributions from U.S. battery deliveries, third-party projects, Asset Vault operating assets, and initial modular...
NYSE:EFC
NYSE:EFCMortgage REITs

Is It Time To Reassess Ellington Financial (EFC) After Recent Share Price Weakness?

Wondering whether Ellington Financial at around US$11.75 is offering good value right now? This article walks you through the key signals to help you frame that question clearly. The stock has seen mixed returns, with a 1.4% decline over the past week, an 8.3% decline over the past month, a 14.1% decline year to date, but gains of 55.4% over 3 years and 33.8% over 5 years. Recent coverage of Ellington Financial has focused on how its share price performance compares with peers and broader...
NYSE:A
NYSE:ALife Sciences

Agilent’s USCAP 2026 Pathology Updates Deepen Oncology Diagnostics Narrative

Agilent Technologies (NYSE:A) has introduced new digital pathology advances and expanded its oncology diagnostics portfolio at the USCAP 2026 Annual Meeting. The company is highlighting integrated, data driven tools designed to support precision oncology diagnostics and automation ready pathology workflows. The announcements reflect Agilent’s focus on scalable lab solutions that connect instruments, software, and data across clinical pathology settings. Agilent Technologies, trading at...